Limitations of this study include the small sample size, absence of longitudinal data, and lack of other biomarkers such as CSF or plasma measurements of Aβ, tau, neurofilament, or neuroimaging biomarkers of AD (amyloid or tau PET imaging). This evidence concerns the gene MAPT and Alzheimer disease.